BK and JC polyomaviruses are known to infect humans ([@R1]*,*[@R2]). Recently, the novel KI polyomavirus (KIPyV) and WU polyomavirus (WUPyV) have been identified in respiratory secretions of children with signs of acute respiratory disease ([@R3]*,*[@R4]). However, there is little evidence that these viruses are the causative agents of respiratory disease. The pathogenic role of these viruses in immunocompromised patients is also unclear.

In a study that investigated human polyomaviruses in autopsy lymphoid tissue samples from patients who were positive for HIV, KIPyV was detected in 7.1% of immunocompromised patients with AIDS and in 1.8% of nonimmunocompromised controls; WUPyV was detected in 9.5% of patients with AIDS but not in controls ([@R5]). We detected KIPyV and WUPyV in 3.2% and 1.6%, respectively, of plasma samples from HIV-1--infected patients ([@R6]). To determine an association between infection with KIPyV and WUPyV and CD4+ cell counts, we obtained plasma samples from HIV-1--positive patients having high and low CD4+ cell counts and a group of healthy controls and tested them for these 2 polyomaviruses.

The Study
=========

Plasma specimens from 153 HIV-1--infected persons (75% male patients, median age 41.9 years, interquartile range 33.8--47.3 years) with high (110 persons) and low (43 persons) CD4+ counts and from 130 blood donors (80% male donors, median age 41 years, interquartile range 32--47.5 years) were obtained at the Foundation Polyclinic Tor Vergata in Rome, Italy, during 2004--2009. Of 153 HIV-1--infected patients, 74 were receiving highly active antiretroviral therapy: a nucleoside reverse transcriptase inhibitor (NRTI) and a protease inhibitor (PI) (n = 35 patients); an integrase inhibitor (INI), an NRTI, and a PI (n = 7); a nonnucleoside-reverse transcriptase inhibitor and an NRTI (n = 26); an INI and an NRTI (n = 2); an INI and an NNRTI (n = 2); a chemokine receptor type 5 antagonist, an NRTI, and a PI (n = 1); and a chemokine receptor type 5 antagonist, an INI, and a nonnucleoside-reverse transcriptase inhibitor (n = 1). Sixty patients did not receive any therapy. No information was available for 19 patients. Additional information available for patients included HIV-1 viremia and co-infection with hepatitis B virus and hepatitis C virus.

Phylogenetic analysis of the small T antigen gene of KIPyV and WUPyV was performed as described ([@R6]*,*[@R7]). GenBank accession numbers of the sequences used in this analysis are shown in the [Table A1](#TA.1){ref-type="table"}.

Total DNA was extracted from 0.2-mL plasma samples by using QIAamp DNA Mini Kit (QIAGEN, Milan, Italy) according to the manufacturer's instructions and stored at --80°C until analysis. Amplification of KIPyV and WUPyV was conducted as described ([@R8]*,*[@R9]). A standard curve was created in a 4-log range by using 1:10 serial dilutions of a virus-specific standard. The dynamic range was determined by using 10-fold dilutions (10^10^--100 copies/reaction) of each sample. Sensitivity of the 2 methods, which corresponded to the lowest plasma dilution detectable at a frequency of 100%, was evaluated. The dynamic range was 10^2^--10^10^ for KIPyV and 10^1^--10^10^ for WUPyV.

Statistical analysis was performed by using Epi Info version 3.5.1 software (Centers for Disease Control and Prevention, Atlanta, GA, USA). Odds ratios were determined for associations between infection with HIV and infection with KIPyV and WUPyV and other variables. Statistical significance was assessed by calculating 95% confidence intervals (CIs) and by using standard nonparametric statistics.

Real-time PCR detected KIPyV and WUPyV in 4 (2.6%) of 153 and 7 (4.6%) of 153 HIV-1--infected patients, respectively ([Table 1](#T1){ref-type="table"}). Of the 130 blood donors examined, 4 and 1 were positive for KIPyV (3.1%) and WUPyV (0.8%), respectively. For KIPyV, no difference was detected in the frequency of infection between HIV-1--infected patients and blood donors. Patients infected with HIV-1 had a higher risk for infection with WUPyV infection than did blood donors. However, this difference showed borderline statistical significance (odds ratio 6.15, 95% CI 0.93--141; p = 0.054). For WUPyV-positive and KIPyV-positive patients, median CD4+ cell counts were 308 cells/µL (95% CI 248--523 cells/µL) and 356 cells/µL (95% CI 270--517 cells/µL), respectively. No association was observed between CD4+ cell counts and risk for infection with KIPyV or WUPyV.

###### Characteristics of 153 HIV+ persons tested for infection with WU and KI polyomaviruses, Italy, 2004--2009\*†

  Characteristic                WUPyV+, n = 7         WUPyV--, n = 146         KIPyV+, n = 4             KIPyV--, n = 149
  ----------------------------- --------------------- ------------------------ ------------------------- -------------------------
  CD4+ cells/µL                                                                                          
  [\<]{.ul}200                  1 (14.3)              45 (30.8)                                          46 (30.9)
  \>200                         6 (85.7)              101 (69.2)               4 (100)                   103 (69.1)
  Median (95% CI)               308 (248--523)        282 (153--378)           356 (270--517)            281 (154--378)
  Virus load, copies/reaction                                                                            
  [\<]{.ul}100,000              7 (100)               99 (67.8)                2 (50)                    104 (69.8)
  \>100,000                                           47 (32.2)                2 (50)                    45 (30.2)
  Median (95% CI)               3,210 (108--36,895)   37,460 (5,490−152,000)   60,636 (2,791--246,500)   34,905 (4,980--145,200)
  Co-infection                                                                                           
  Yes                           2‡ (28.6)             29 (19.9)                2§ (50)                   29 (19.5)
  No                            5 (71.4)              117 (80.1)               2 (50)                    120 (80.5)

\*Values are no. (%) unless otherwise indicated. WUPvV, WU polyomavirus; KIPyV, KI polyomavirus; CI, confidence interval. †Of the 153 persons tested, 115 (75.2%) were men, 38 (24.8%) women. A total of 130 blood donors (104 \[80%\] men, 26 \[20%\] women) were also tested; 1 (0.8%) was WUPyV+ and 4 (3.1%) were KIPyV+. ‡Co-infection with hepatitis virus. §Co-infection with hepatitis C virus and hepatitis B virus.

Median HIV-1 virus load in persons infected with WUPyV or KIPyV was 3,210 copies/mL (95% CI 108--36,895 copies/mL) or 60,636 copies/mL (95% CI 2,791--246,500 copies/mL), respectively. When HIV-1 virus load, CD4+ cell count, and co-infection with hepatitis B and C viruses were analyzed in patients infected with KIPyV or WUPyV, no association was found. Of 11 patients infected with KIPyV or WUPyV, 6 received highly active antiretroviral therapy and 5 did not receive any therapy ([Table 2](#T2){ref-type="table"}).

###### Treatment regimens for 11 HIV-1--positive patients co-infected with KI or WU polyomavirus, Italy, 2004--2009\*

  Patient no.   KIPyV   WUPyV   HAART
  ------------- ------- ------- ------------------------------
  1             \+      --      None
  2             \+      --      None
  3             \+      --      None
  4             \+      --      NRTI: FTC, TDF; PI: ATV, RTV
  5             --      \+      NNRTI: EFV; NRTI: 3TC, TDF
  6             --      \+      NNRTI: NVP; NRTI: 3TC, AZT
  7             --      \+      NRTI: 3TC, AZT; PI: ATV, RTV
  8             --      \+      NNRTI: NVP; NRTI: ABC, TDF
  9             --      \+      None
  10            --      \+      NNRTI: EFV; NRTI: 3TC, D4T
  11            --      \+      None

\*KIPyV, KI polyomavirus; WUPyV, WU polyomavirus; HAART, highly active antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; FTC, emtricitabine; TDF, tenofovir; PI, protease inhibitor; ATV, atazanavir; RTV, ritonavir; NNRTI, nonnucleoside reverse transcriptase inhibitor; EFV, Efavirenz; 3TC, lamivudine; NVP, nevirapine; AZT, azidothymidine; ABC, D4T, stavudine.

Phylogenetic analysis showed that all WUPyVs identified in this study except WUV-IT4 are closely related to the WUV-IT3 strain identified in an HIV-1 patient ([@R6]) ([Figure](#F1){ref-type="fig"}). The KIPyV strains identified are relatively distant from those identified in another study ([@R6]), except for strain KIV-RM23, which clusters with KIV-RM21 ([@R6]) ([Figure](#F1){ref-type="fig"}).

![Maximum likelihood phylogenetic analysis of KI polyomavirus (KIPyV) and WU polyomavirus (WUPyV) small T antigen sequences. Strains identified in this study are in **boldface**. The tree was rooted by using the midpoint rooting method. Branch lengths were estimated by using the best fitting nucleotide substitution (Hasegawa, Kishino, and Yano) model according to a hierarchical likelihood ratio test ([@R6],[@R7]) and were drawn to scale. Scale bar indicates 0.8 nt substitutions per site. Asterisks along the branches indicate significant statistical support for the clade subtending that branch (p\<0.001 by the zero-branch-length test and bootstrap support \>65%).](10-0211-F){#F1}

Conclusions
===========

KIPyV and WUPyV have been identified in respiratory secretions of pediatric patients ([@R3]*,*[@R4]). New polyomaviruses have also been detected in immunocompromised patients ([@R10]*--*[@R13]). However, the pathogenic role of these polyomaviruses in immunocompromised patients is unclear. No associations were found between CD4+ cell counts in HIV-1--positive patients and infection with KIPyV or WUPyV. Frequency of KIPyV infection for HIV-1--positive patients was similar to that for blood donors. However, frequency of WUPyV infection was higher for HIV-1--positive patients than for blood donors, although this difference showed borderline significance.

Detection of WUPyV did not show a correlation with virus load for HIV-1 or lower CD4+ cell counts. Seroprevalence of KIPyV and WUPyV in an adult population was 55% and 69%, respectively ([@R14]). The higher rate of infection for WUPyV may account for the higher rate of detection for WUPyV in our study population. In a previous study ([@R6]), prevalence of WUPyV in plasma of HIV-1--positive patients was lower than that in our study. This difference may have been caused by the larger sample size in our study.

Phylogenetic analysis did not suggest circulation of specific KIPyV and WUPyV strains in HIV-1--positive patients. The KIPyVs identified in this study cluster with those identified in HIV-1--positive patients, and the WUPyVs identified are closely related to the strain identified previously in an HIV-1--positive patient ([@R6]). However, these WUPyV strains also cluster with strain WUV-IT1 and 2 strains identified in stool samples ([@R10]).

Our study design and the complex nature of AIDS-related disease do not enable one to make definitive conclusions on the role of novel polyomaviruses in HIV-1--positive patients. However, our data seem to exclude an active role for KIPyV and WUPyV in HIV-1--positive patients.

We detected WUPyV and KIPyV in healthy persons and immunocompromised persons. BK and JC polyomaviruses persist in peripheral blood mononuclear cells in healthy persons ([@R15]). However, frequency of detection may vary from 0% to 90% of persons tested. This large variation may reflect recent infection or virus reactivation in a subgroup of persons ([@R15]). Thus, detection of KIPyV and WUPy in blood cells of immunocompetent persons is needed to identify a possible hematologic reservoir.

*Suggested citation for this article*: Babakir-Mina M, Ciccozzi M, Farchi F, Bergallo M, Cavallo R, Adorno G, et al. KI and WU polyomaviruses and CD4+ cell counts in HIV-1--infected patients, Italy. Emerg Infect Dis \[serial on the Internet\]. 2010 Sep \[*date cited*\]. <http://dx.doi.org/10.3201/eid1609.100211>
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###### KI and WU polyomavirus sequences used in phylogenetic analysis, Italy, 2004--2009

  Virus                GenBank accession no.   Type of sample
  -------------------- ----------------------- ----------------
  KIV Stockholm60      NC_009238               Respiratory
  KIV Brisbane 002     EF520288                Respiratory
  KIV Stockholm 380    EF127908                Respiratory
  WU/Wuerzburg/03/07   EU711058                Respiratory
  WU/Wuerzburg/02/07   EU711057                Respiratory
  WU/Wuerzburg/01/07   EU711056                Respiratory
  WU/Wuerzburg/01/06   EU711055                Respiratory
  WU/Wuerzburg/01/03   EU711054                Respiratory
  WUV CU-302           EU358769                Respiratory
  WUV CU-295           EU358768                Respiratory
  WUV CLFF             EU296475                Respiratory
  WUV S5               EF444554                Respiratory
  WUV S4               EF444553                Respiratory
  WUV S3               EF444552                Respiratory
  WUV S2               EF444551                Respiratory
  WUV S1               EF444550                Respiratory
  WUV B0               EF444549                Respiratory
  KIV-RM4              FJ389516                Lung tissue
  KIV- RM3             FJ389515                Lung tissue
  KIV- RM2             FJ389514                Lung tissue
  KIV-RM5              FJ594126                Stool
  KIV-RM6              FJ594124                Stool
  KIV-RM7              FJ594125                Stool
  KIV-RM8              FJ594120                Stool
  KIV-RM9              FJ594121                Stool
  KIV-RM10             FJ594122                Stool
  KIV-RM11             FJ594123                Stool
  WUVIT3               FJ842114                Plasma
  KIV-RM22             FJ842113                Plasma
  KIV-RM21             FJ842112                Plasma
  WUV-IT2              FJ594119                Stool
  WUV-IT1              FJ594118                Stool
  KIV-RM13             FJ811519                Tonsil tissue
  KIV-RM14             FJ811520                Tonsil tissue
  KIV-RM15             FJ811521                Tonsil tissue
  KIV-RM16             FJ811522                Tonsil tissue
  KIV-RM17             FJ811523                Tonsil tissue
  KIV-RM18             FJ811524                Tonsil tissue
  KIV-RM20             FJ821706                Tonsil tissue
  KIV-RM23             HM164689                Plasma
  KIV-RM24             HM164690                Plasma
  KIV-RM25             HM164691                Plasma
  KIV-RM26             HM164692                Plasma
  WUV-IT4              HM164682                Plasma
  WUV-IT5              HM164683                Plasma
  WUV-IT6              HM164684                Plasma
  WUV-IT7              HM164685                Plasma
  WUV-IT8              HM164686                Plasma
  WUV-IT9              HM164687                Plasma
  WUV-IT10             HM164688                Plasma
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